GVS
870976
Hangzhou CNCR-IT
300250
Shanghai Newtouch Software
688590
4
Ucap Cloud Information Technology Co.,Ltd
688228
5
Yangtze Optical Electronic
688143
US Stock MarketDetailed Quotes
LRMR Larimar Therapeutics
- 3.580
- -0.050-1.38%
Close Jan 24 16:00 ET
- 3.580
- 0.0000.00%
Post 20:01 ET
228.43MMarket Cap-3.11P/E (TTM)
3.780High3.540Low1.27MVolume3.730Open3.630Pre Close4.69MTurnover4.03%Turnover RatioLossP/E (Static)63.81MShares13.68052wk High1.15P/B113.20MFloat Cap3.01052wk Low--Dividend TTM31.62MShs Float664.320Historical High--Div YieldTTM6.60%Amplitude1.530Historical Low3.678Avg Price1Lot Size
Trending Stocks
Discussing
January rate meeting coming! Fed's pause in rate cuts a foregone conclusion?
🎙️Discussion 1. Will the Fed press the "pause button" on rate cuts as expected? 2. Do you think President Trump's political actions will ch
In One Chart
Jan 15 22:05
Here's the Breakdown for December CPI, in One Chart
Larimar Therapeutics Stock Forum
Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich's Ataxia
Thursday, 23rd January at 4:05 pm
• Adolescents receive a weight-based dose equivalent to the 50 mg adult dose
• Adolescents 12-17 years old who complete participation in the pharmacokinetic (PK) run-in study will be eligible to screen in the ongoing open label extension (OLE) study
• Larimar is continuing to enrol...
Larimar Therapeutics Announces Positive Initial Data from Ongoing Long-term Open Label Extension Study & Progress Across Nomlabofusp Program for Friedreich's Ataxia
Monday, 16th December at 7:00 am
• Daily subcutaneous injections of 25 mg nomlabofusp in 14 participants were generally well tolerated for up to 260 days in the ongoing open label extension (OLE) study
• Tissue frataxin (FXN) levels showed mean change from baseline of 1.32 pg/μg in buccal cells a...
No comment yet